NCT06287723 is a clinical trial of Blood sample/Liquid biopsy in Colorectal Cancer, sponsored by University Hospital, Montpellier.

Who is sponsoring NCT06287723?

NCT06287723 is sponsored by University Hospital, Montpellier.

What drugs are being tested in NCT06287723?

Interventions in NCT06287723: Blood sample/Liquid biopsy.

What condition does NCT06287723 study?

NCT06287723 studies Colorectal Cancer, Liver Metastases, Stage IV Colorectal Cancer, Minimal Residual Disease, Liquid Biopsy, ctDNA.

Is NCT06287723 still recruiting?

NCT06287723 is currently not yet recruiting. Last updated 1 March 2024.

Last reviewed 2024-03-01 · How we verify

NCT06287723

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)

Not yet recruiting Last updated 1 March 2024

What this trial tests

trial testing Blood sample/Liquid biopsy in Colorectal Cancer in 30 participants. Not yet recruiting.

Timeline

1 March 2024

Primary endpoint
31 October 2025

31 October 2028

Quick facts

Lead sponsor	University Hospital, Montpellier
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	30
Start date	1 March 2024
Primary completion	31 October 2025
Estimated completion	31 October 2028

Drugs / interventions tested

Blood sample/Liquid biopsy — full drug profile →

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →
Liver Metastases — all drugs for Liver Metastases →
Stage IV Colorectal Cancer — all drugs for Stage IV Colorectal Cancer →
Minimal Residual Disease — all drugs for Minimal Residual Disease →

Sponsor

University Hospital, Montpellier

Who can join

18 and older, any sex, with Colorectal Cancer or Liver Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for colorectal cancer, the methods used to decide who gets additional post-surgery treatment are suboptimal. Some patients get too much treatment, while others do not get enough. There is a new way to explore if there is any cancer left in a patient's body using circulating tumor DNA (ctDNA) detected in blood samples. This can help decide who needs more treatment after surgery. Even though many tests have been developed, it has yet to be determined which test performs best at relevant time points. The GUIDE.MRD consortium is a group of experts, including scientists, technology, and pharmaceutical companies. The consortium is working on creating a reliable standard for the ctDNA tests, validating their clinical utility, and collecting data to help decide on the best treatment for each patient. FRENCH.MRD.CRLM is the French study and part of the european GUIDE.MRD project.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing.
Kobayashi S, Nakamura Y, Hashimoto T, Bando H, et al · · 2025 · cited 6× · PMID 39920551 · DOI 10.1007/s10147-024-02683-0
Liquid Biopsies in the Early Diagnosis, Prognosis, and Tailored Treatment of Colorectal Cancer.
Liatsou E, Kollias I, Trapali M, Tsilimigras DI, et al · · 2025 · cited 4× · PMID 40149264 · DOI 10.3390/cancers17060927

Verify or expand the search:

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Other University Hospital, Montpellier trials

Trials by the same sponsor.

NCT07524127 — Phenotyping of Type 2 Inflammation Profile by Rheology of Nasal Secretions and Tissue Quantification of Eosinophilic Pol · NA · not yet recruiting
NCT07255495 — Effects of Neuromuscular Scoliosis Surgery on Nutritional Metabolism · NA · not yet recruiting
NCT07534189 — Prospective Cohort Study Evaluating a Thermal Spa Programme in Symptomatic Knee Osteoarthritis · NA · not yet recruiting
NCT07515638 — Immun4Cure Cohort of Autoimmune Diseases · not yet recruiting
NCT07406516 — Identification of Kinematic Variables Specific of Patellar Tendinopathy in Athletes at Risk · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06287723 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Montpellier
Last refreshed: 1 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06287723.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing